Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe

BETHESDA, Md.--(BUSINESS WIRE)--Northwest Biotherapeutics (OTCBB:NWBO) ("NWBT") announced today a $4.55 million equity investment on June 28, 2011, by The Richard M. Schulze Family Foundation (the "Foundation"). The sale of newly issued common stock of the Company to the Foundation follows the investment of $3 million, on May 31, 2011, by investment funds managed by Whitebox Advisors, a multi-billion-dollar hedge fund group headquartered in Minneapolis, Minnesota ("Whitebox"). The Foundation has been focused for a number of years on game-changing medical research and treatment breakthroughs. The Foundation has been a major supporter of basic research at universities, and clinical programs at medical centers such as the University of Minnesota and the Mayo Clinic.

“It is gratifying to see growing support for our vision of DCVax® as a more effective, non-toxic, easier to administer, and less expensive new treatment for multiple cancers.”

NWBT is developing DCVax^® immune therapies for personalized treatment of a wide range of cancers. DCVax^® is a platform technology which uses a patient’s own dendritic cells (the master cells of the immune system), and biomarkers of the patient’s specific type of cancer. In essence, the dendritic cells are activated and “educated” to recognize that patient’s cancer and mobilize the patient’s immune system to attack it. As such, DCVax^® is a non-toxic, broad platform technology which is expected to be applicable to most cancers.

The Company’s lead product candidate is DCVax^®-L, which targets solid tumor cancers (i.e., cancers in various tissues) such as Glioblastoma multiforme (‘‘GBM’’), the most lethal form of brain cancer. DCVax^®-L for GBM is currently in a 240-patient Phase II clinical trial. In prior clinical trials of DCVax^®-L for GBM, the results have been striking. The patients who received DCVax^®-L showed a median survival of 3 years, compared with median survival of only 14.6 months with standard of care today (surgery, radiation and chemotherapy). The patients treated with DCVax^®-L did not have their tumor recur for approximately 2 years, on average, as compared with tumor recurrence in just 7 months with standard of care today. Moreover, these patients did not experience any toxicity from DCVax^®-L.

“With these additional resources from the Foundation and Whitebox, augmented by the $25 million equity financing facility through Toucan Capital which we recently announced, NWBT now has a strong resource base to pursue the completion of its clinical trials and progress toward commercialization,” said Ms. Linda Powers, CEO of NWBT. “It is gratifying to see growing support for our vision of DCVax^® as a more effective, non-toxic, easier to administer, and less expensive new treatment for multiple cancers.”

“I am impressed by the clinical trial results to date, and encouraged that the Company is pursuing these trials in both the US and Europe,” commented Richard M. Schulze, President of The Richard M. Schulze Family Foundation. “I share NWBT’s vision that with its cost-effective manufacturing, and the simplicity of the DCVax^® product, like a flu shot, this new treatment can be made available at reasonable cost to patients.”

About Whitebox Advisors

Whitebox Advisors is an SEC-registered investment adviser located in Minneapolis, Minnesota. Founded in 2000, the firm currently manages over $2.5 billion and employs 65 professionals.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and certain therapeutic antibodies. The Company’s lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme (“GBM”), the most aggressive and lethal form of brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has also conducted a Phase I/II trial with DCVax^® for recurrent metastatic ovarian cancer. The Company’s second technology platform, involving antibodies to CXCR4, is at the pre-clinical development stage.

For further information about clinical sites and Company information, please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax^®-L and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expects,” “believes,” “intends,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company’s products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.